---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-003205"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:12:31.213108+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health closes exclusive global distribution deal for BreastCheck non-invasive breast test

## Summary
- Closed sub-license with NeuRX Health granting subsidiary Odyssey Medical Devices exclusive worldwide marketing and distribution rights for BreastCheck.
- BreastCheck is a non-invasive, 15-minute test for breast abnormalities, registered with FDA, EU, and UK regulators.
- Global breast cancer screening market estimated at $26B; commercial sales expected to begin in H2 2026.
- CEO Michael Redmond says agreement provides clear pathway to near-term revenue and supports growth strategy.

## SEC filing metadata
- accession: 0001683168-26-003205
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316826003205/0001683168-26-003205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316826003205/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-003205
- JSON: https://secwatch.observer/filing/0001683168-26-003205.json
- Plain text: https://secwatch.observer/filing/0001683168-26-003205.txt

## Source-grounded claims
- claim_id: 8a09534d2a1e4dd89b71c1b320196f0ec33be8c1
  claim: Odyssey Health, Inc. entered into Master Technology and Sub-license Agreement with NeuRX Health, Inc. (effective 2025-10-14).
  evidence_excerpt: On April 21, 2026, Odyssey Health, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) successfully closed the Master Technology and Sub-license Agreement (the “ Agreement ”) with NeuRX Health, Inc. (“ NeuRX ”) which was entered into on October 14, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626644/000168316826003205/0001683168-26-003205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.